By Image Credit,The Bridge

Copyright thebridge

Curecell, a company developing ferroptosis inhibitors, announced on the 24th that it will conduct a Pre-A round through equity-based crowdfunding on e-Crowd, aiming to raise up to ¥50 million through the issuance of new shares. The fundraising will take place from September 25 to October 14, with investors being individuals and specific investors through e-Crowd. According to e-Crowd, the project is expected to qualify for Angel Taxation A and B.

The company is advancing drug development using the apomorphine derivative “Apoethylmorphine” to inhibit ferroptosis, a type of cell death caused by the accumulation of iron-dependent peroxides. According to the company, ferroptosis is reported to be involved in over 100 diseases, including myocardial infarction, cerebral infarction, and Parkinson’s disease, and they aim to expand applications for both therapeutic and preventive drugs. Curecell’s vision is to “extend healthy life expectancy through anti-aging.”

The Apoethylmorphine under development possesses both antioxidant and anti-inflammatory properties and has obtained use patents for 30 types of diseases and symptoms, including myocardial infarction and diabetes (Japanese Patent No. 7360229, owned by Jichi Medical University). Patents are also held in the United States, China, and South Korea, with applications pending in the EU and India. The company has received exclusive implementation rights with sublicensing rights from Jichi Medical University, allowing for in-house development as well as joint development and licensing business opportunities.

The funds raised will be allocated to the non-clinical trial costs of Apoethylmorphine. After completing the non-clinical trials, the company plans to promptly transition to clinical trials, aiming for approval as a pharmaceutical product, while also considering market entry as a quasi-drug according to their plans.

CureSel was established in August 2022, and its current capital is 23.9 million yen. This will be the company’s first large-scale fundraising round.

Reference Links:

Jichi Medical University Ferroptosis Research